ELI Lilly Australia has agreed with owner Acrux to cease promoting the transdermal testosterone solution Axiron, returning the product to its maker who currently has no plans to commercialise it in Australia.
In a Dear Healthcare Professional letter, the company pointed out that the product was not 'A-flagged' and could not therefore be substituted at the pharmacy level.
Patients, estimated at around 2,500 men according to Besins Healthcare, will need to visit their doctors and seek an alternative prescription if they wish to continue testosterone replacement therapy.
Besins, the manufacturer of testosterone replacement therapy Testogel (1% transdermal testosterone gel) is hoping to pick up patients impacted by the sudden withdrawal of Axiron, and to this end is intensifying its promotion to doctors and upping its manufacturing production, said Besins md Geoff Blundell.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Nov 17
